ORCA therapeutics

ORCA Therapeutics B.V. is a privately-funded biopharmaceutical company designing and developing new oncolytic immunotherapies for treatment of cancer using Oncolytic Replication Competent Agents (ORCA). At ORCA, we are passionate about using viruses to cure cancer patients. Our proprietary technologies allow us to engineer powerful oncolytic adenoviruses that selectively kill cancer cells and induce an antitumor immune response. ORCA’s lead compound ORCA-010 is being developed for treatment naive patients with prostate cancer.